Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1251 - 1275 of 1683 in total

Carfilzomib

Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Approved
Investigational
Matched Description: … Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. ... FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … KYPROLIS POWDER FOR SOLUTION FOR INFUSION 60MG/VIAL ... KYPROLIS POWDER FOR SOLUTION FOR INFUSION 30 MG/VIAL ... Kyprolis (carfilzomib) powder for solution for infusion 60mg/vial …

Irinotecan

Irinotecan is a topoisomerase inhibitor used for chemotherapy. It is a water-soluble analogue of camptothecin, which is extracted from the Chinese tree Camptotheca acuminate. The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility. As an anticancer drug, irinotecan was first commercially available in Japan in 1994...
Approved
Investigational
Matched Description: … Irinotecan is a topoisomerase inhibitor used for chemotherapy. ... Both irinotecan and SN-38 mediate antitumor activity by forming a complex with topoisomerase I and blocking ... irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and …
Matched Salts name: … Irinotecan hydrochloride hydrate …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Products: … IRITEC CONCENTRATE FOR SOLUTION FOR INFUSION 40mg/2ml ... IRITEC CONCENTRATE FOR SOLUTION FOR INFUSION 100mg/5ml ... IRINOTESIN (20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION) …

Zoledronic acid

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid...
Approved
Matched Description: … [A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia ... third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and ... of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. …
Matched Categories: … zoledronic acid, calcium and colecalciferol, sequential ... Drugs for Treatment of Bone Diseases ... Drugs Affecting Bone Structure and Mineralization …
Matched Products: … ZOVA CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML ... ZOLETEM CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML ... ZOLENDRAN CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/5ML …

Topotecan

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Approved
Investigational
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Products: … HYCAMTIN (POWDER FOR SOLUTION FOR INFUSION) ... TOCANTIN POWDER FOR SOLUTION FOR INFUSION 4 MG/VIAL ... TOCANTIN POWDER FOR SOLUTION FOR INFUSION 4MG …

Doxorubicin

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed...
Approved
Investigational
Matched Synonyms: … MTC-DOX for Injection …
Matched Description: … [A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain ... Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers. ... generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … DOXABIN POWDER FOR SOLUTION FOR INJECTION 10MG/VIAL ... DOXABIN POWDER FOR SOLUTION FOR INJECTION 50MG/VIAL ... DOXOCCORD CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML …

Levetiracetam

Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918]...
Approved
Matched Description: … It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated ... having generally narrow therapeutic indexes and a propensity for involvement in drug interactions. ... [L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no …
Matched Products: … Levetiracetam in Sodium Chloride ... Keppra Concentrate for Solution for Infusion 100 mg/ml ... INTIRACETAM CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML …

Ferric derisomaltose

Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non...
Approved
Matched Description: … Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. ... This drug is a complex of iron (III) hydroxide and derisomaltose. ... Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately …
Matched Products: … MONOFER® SOLUTION FOR INJECTION OR INFUSION 100 MG/ML ... Monofer 100 mg/ml solution for injection/infusion in vials ... Monofer 100mg/ml solution for injection/infusion in ampoules …

Canakinumab

Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy...
Approved
Investigational
Matched Description: … Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older ... part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and ... It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … Ilaris Powder for Solution for Injection 150mg/vial ... ILARIS 150MG POWDER FOR SOLUTION FOR INJECTION …

Alirocumab

Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which...
Approved
Matched Description: … high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and ... FDA approval was contingent on the completion of further clinical trials to better determine efficacy and ... Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hypolipidemic Agents Indicated for Hyperlipidemia ... Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia …
Matched Products: … PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN) ... PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN) ... PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML …

Golimumab

Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with...
Approved
Matched Description: … Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients ... Golimumab binds and inhibits soluble and transmembrane human TNFα. ... Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Biologics for Rheumatoid Arthritis Treatment …
Matched Products: … Concentrate for Solution for Infusion 12.5mg/1 ml ... SIMPONI SOLUTION FOR INJECTION ... SIMPONI IV 12.5mg/1ml Concentrate for Solution for Infusion …

Insulin glulisine

Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by ... Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. ... Type 1 and Type 2 Diabetes. …
Matched Categories: … Insulins and Analogues for Injection, Fast-Acting ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … APIDRA 100 Units/ml Solution for Injection in vial ... APIDRA 100 U/ML- SOLUTION FOR INJECTION IN VIAL ... Apidra SoloStar 100 Units/ml Solution for injection in a pre-filled pen …

Guselkumab

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological ... market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. ... Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Skin and Mucous Membrane Agents …
Matched Products: … TREMFYA 100MG/ML SOLUTION FOR INJECTION ... TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML ... TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/1ML …

Emicizumab

Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable...
Approved
Investigational
Matched Description: … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017. ... Ltd. and co-developed with Roche and Genentech.[L1015] ... a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Matched Products: … HEMLIBRA 30MG/ML SOLUTION FOR INJECTION ... HEMLIBRA 150MG/ML SOLUTION FOR INJECTION ... HEMLIBRA SOLUTION FOR INJECTION 150MG/ML …

Afoxolaner

Experimental
Vet approved
Matched Mixtures name: … Nexgard Spectra 38mg/8mg Chewable Tablets for Dogs >7.5-15kg ... Nexgard Spectra 9mg/2mg Chewable Tablets for Dogs 2-3.5kg ... Nexgard Spectra 19mg/4mg Chewable Tablets for Dogs >3.5-7.5kg …
Matched Products: … NexGard 11mg chewable tablets for dogs 2-4kg ... NexGard 136mg chewable tablets for dogs > 25-50kg ... NexGard 28mg chewable tablets for dog > 4-10kg …

Agalsidase alfa

Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Categories: … Alimentary Tract and Metabolism ... Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Matched Products: … REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML …

Risankizumab

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Matched Description: … It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and ... [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. ... [L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716] …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Skin and Mucous Membrane Agents …
Matched Products: … SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.83ML ... SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML ... SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML …

Letermovir

Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status...
Approved
Investigational
Matched Description: … [A31290] Letermovir has recieved both priority and orphan drug status from the FDA. ... Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus …
Matched Categories: … Antivirals for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … PREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML ... PREVYMIS 240mg/12mL (20mg/mL) concentrate for solution for infusion ... PREVYMIS 480mg/24mL (20mg/mL) concentrate for solution for infusion …

Avibactam

Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract infections, including pyelonephritis caused by antibiotic resistant-pathogens,...
Approved
Matched Description: … As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 ... infections in combination with metronidazole, and the treatment of complicated urinary tract infections ... This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal …
Matched Salts name: … Avibactam sodium …
Matched Products: … ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 2G/0.5G …

Tetrofosmin

Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.
Approved
Matched Products: … MYOVIEW POWDER FOR INJECTION ... MYOVIEW FOR INJECTION 0.23 mg/vial …

Olipudase alfa

Olipudase alfa is recombinant human acid sphingomyelinase. It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease. ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency...
Approved
Investigational
Matched Description: … [A251590] It is the first and only enzyme replacement therapy in the world for the treatment of Acid ... storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and ... to hydrolyze sphingomyelin accumulated in body tissues, such as the lungs, liver, spleen, kidneys, and …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Enzymes and Coenzymes …
Matched Products: … XENPOZYME 20MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION …

Trastuzumab deruxtecan

Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of...
Approved
Investigational
Matched Description: … The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from ... A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and ... Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL …

Anifrolumab

Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.[A237079,L34929] Three...
Approved
Investigational
Matched Description: … [hydroxychloroquine], glucocorticoids like [dexamethasone], and disease modifying antirheumatic drugs ... [A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that ... The design of early clinical trials of anti-interferon treatments such as anifrolumab, rontalizumab, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … SAPHNELO 300MG CONCENTRATE FOR SOLUTION FOR INFUSION …

Obinutuzumab

Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV)...
Approved
Investigational
Matched Description: … It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. ... There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … GAZYVA 1000 MG/ 40 ML CONCENTRATE FOR SOLUTION FOR INFUSION ... GAZYVA CONCENTRATE FOR SOLUTION FOR INFUSION 1000MG/40ML …

Necitumumab

Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and...
Approved
Investigational
Matched Description: … Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment ... for metastatic squamous non-small cell lung cancer (NSCLC). ... It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … PORTRAZZA CONCENTRATE FOR SOLUTION FOR INFUSION 800MG/50ML …

Eptinezumab

Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).[F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment...
Approved
Investigational
Matched Description: … [L12318] Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human ... Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed ... [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Products: … VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML …
Displaying drugs 1251 - 1275 of 1683 in total